Emzor Pharmaceutical Industries Limited commemorates World Malaria Day 2025, reaffirming its dedication to combating malaria in Nigeria and Sub-Saharan Africa. The company aligns with the year's theme, “Malaria Ends With Us: Reinvest, Reimagine, Reignite,” reflecting Emzor's vision for a significant impact in the global fight against malaria.

Mr. Kunle Faloye, Head of Marketing and Strategy at Emzor, stated that the company has been at the forefront of malaria prevention and treatment by producing accessible and affordable antimalarial medications. Emzor's commitment includes investments in research, development, and distribution networks, which have been crucial in reducing the malaria burden.

To mark World Malaria Day 2025, Emzor organized community outreach activities such as health walks, free medical screenings, and the distribution of antimalarial drugs to vulnerable populations. Malaria remains a leading cause of death among pregnant women and children under five in Africa, and Emzor's initiatives include the production of essential antimalarial drugs to reduce maternal and infant mortality rates.

Emzor produces over 20 antimalarial SKUs, including Maldox (Sulfadoxine/Pyrimethamine), Lokmal (Artemether/Lumefantrine), Piramal TS (Dihydroartemisinin/Piperaquine), Diasunate (Artesunate/Amodiaquine), and Chloroquine, available in tablets, suspensions, and dispersible tablets.

Emzor has invested in the manufacture of Active Pharmaceutical Ingredients (API) at its modern manufacturing Pharmaceutical Campus in Sagamu, Ogun State. The plant will initially focus on producing antimalarial APIs, specifically Arthemeter, Lumefantrine, Sulfadoxine, and Pyrimethamine. These APIs support the WHO-recommended treatments for malaria in adults and children, as well as chemo-preventive combination therapies for pregnant women and children under five.

This investment aims to boost Nigeria’s capacity to locally produce a broad range of antimalarial drugs, improving access to high-quality treatments across sub-Saharan Africa. The project will reduce Nigeria’s dependence on imports, support GDP growth, reduce foreign exchange demand, and lower production costs, making life-saving medicines more accessible.

Mr. Emeka Okoli, Chairman of the Board of Directors of Emzor Pharmaceutical Industries Limited, emphasized that since approximately 95% of all malaria cases and 96% of deaths occur in Africa, solutions should largely come from the continent. Emzor is contributing by pioneering the API project in Africa.

Emzor also partners with local governments, NGOs, and communities to implement grassroots outreach programs focused on education, prevention, diagnosis, and treatment. The company provides subsidized and free medications to pregnant women and children, who are most vulnerable to malaria.

Mr. Faloye added that Emzor remains committed to contributing to global efforts toward malaria eradication through innovation, collaboration, and investment in sustainable healthcare solutions.